

From: John Lloyd <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 10/17/2016 8:22:56 AM
Subject: New Evolutions in Targeted RNA Drug Delivery Systems | Hear from MHRA, GSK, AstraZeneca, Roche and Novartis

Hear progressive insights into emerging RNA Technologies at:

RNA Therapeutics 2017

8th Annual Conference: 22nd & 23rd Feb | Interactive Workshop: 21st Feb
Cophorne Tara Hotel, London, UK
Proudly Sponsored by: Lipocalyx

www.therapeutics-rna.com - £400 saving ends 31st Oct

Download a brochure to see the full line-up of industry leading speakers and scientific pioneers!

Dear Mr Tony Kester,

Bringing in voices from some of the most senior industry thought leaders in drug delivery, formulation and regulation, SMI's 8th annual **RNA Therapeutics** conference returns to Central London in February 2017 to discuss new evolutions in nanotechnology and targeted drug delivery systems.

If you haven't seen the brochure yet, scroll down for agenda highlights or [visit the website](#) to see a detailed programme and full speaker line-up.

Day 1 will address topics such as small activating RNA (**saRNA**), progress in emerging **oligonucleotide** drugs, locked **nucleic acids**, personalised **immunotherapy**, and new concepts to conducting **drug discovery**; while **Day 2** explores key issues surrounding third generation **antisense technology**, RNAi therapy **regulation**, **patent submission** guidance, **nanotherapeutics**, intravenously injectable RNA **nanomedicines**, and **spherical nucleic acids**.

EVENT HIGHLIGHTS FOR 2017:

- Hear new updates on **saRNA clinical applications** in an opening keynote from MiNA Therapeutics Co-Founder, Nagy Habib.
- Stay at the forefront of clinical breakthroughs with recent evidence on mRNAs based **cancer therapy**.
- Roche optimise the drug delivery process and provide exciting new insight into **locked nucleic acids**.
- Next generation RNA delivery vehicles - **exclusive data** presented on how exosomes have evolved a specific route for cell entry.
- Thought provoking talk on the **first antisense report** from 1978 and the journey so far.
- Special **MHRA keynote** address offering regulatory guidance on RNAi therapies.
- Expand your scientific horizons on the potential power of image guidance in **nanoparticle** mediated RNAi effector delivery.
- **Protect your innovations** through expert advice on patent applications.
- Learn from detailed **phase II clinical trial results** on protecting the kidney using siRNA targeting p53.

This is just a quick preview of what to expect. Visit the [website](#) for a detailed agenda and information on the **pre-conference interactive workshop**.

HOW TO REGISTER - £400 saving expires 31st Oct

- Online at www.therapeutics-rna.com
- For **sponsorship opportunities** contact Alia Malick at amalick@smi-online.co.uk or call +44 (0)20 7827 6168
- For **delegate enquiries** contact Fateja Begum at fbegum@smi-online.co.uk or call +44 (0)20 7827 6184

AGENDA HIGHLIGHTS: [Download brochure](#)

Day One - 22nd Feb 2017	Day Two - 23rd Feb 2017
8.30 Registration & Coffee	8.30 Registration & Coffee
9.00 Chairman's Opening Remarks Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London	9.00 Chairman's Opening Remarks Heinrich Haas, VP RNA Formulation and Drug Development, BioNTech AG
9.10 RNA activation and its clinical application Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London	9.10 Antisense in the fourth decade: Third generation antisense (3GA) fulfilling the promise Sudhir Agrawal, President & C S O, Idera Pharmaceuticals
9.50 Collaborating to deliver macromolecules across biological barriers — a review of IMI COMPACT Steve Hood, Director, Scinovo, GSK	9.50 Interacting with the medicines regulator on RNAi therapies John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
10.30 Morning Coffee	10.30 Morning Coffee
11.00 Delivery of mRNA using the Viromer® system Steffen Panzner, Managing Director, Lipocalyx	11.00 Nano-therapeutics; the best of all possible worlds? Andrew Miller, CSO, KP Therapeutics Ltd
11.40 Therapeutic antisense oligonucleotides in oncology Mark Edbrooke, Senior Principal Scientist, AstraZeneca	11.40 Protecting your innovative products and methods: How to patent RNA therapeutics Mark Chapman, Partner, Carpmaels & Ransford
12.20 Networking Lunch	12.20 Networking Lunch
1.30 RNA Therapeutics Harnessing the Potential of Locked Bo Rode Hansen, Director, Technology and Partnered Discovery, Santaris Pharma A/S	1.30 Intravenously injectable RNA Nanomedicines as cancer vaccines: case study with RNA-Lipoplexes Heinrich Haas, VP RNA Formulation and Drug Development, BioNTech AG
2.10 Sites of RNA silencing: Cell entry of exosomes as a novel paradigm for therapeutic RNA delivery Nicole meisner-kober, Senior Investigator, Novartis Institutes for Biomedical Research	2.10 The challenges and lessons learnt about the delivery of small and large nucleic acids to cancers Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
2.50 Afternoon Tea	2.50 Afternoon Tea
3.20 RNAi and tumor microenvironment: pre-clinical and clinical evidence Amotz Shemi, CEO, Silenseed	3.20 Protecting the kidney: using siRNA targeting p53 to prevent and ameliorate acute kidney injury and delayed graft function Shai Erlich, VP, Pharmaceutical Development, Quark Biotech Inc
4.00 Individualized mRNA-based cancer immunotherapy Andreas Kuhn, Vice President RNA Biochemistry & Manufacturing, BioNTech	4.00 Spherical Nucleic Acids: Structures for topical gene regulation David Giljohann, CEO, Excicure Inc.
4.40 Chairman's Closing Remarks and Close of Day One Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London	5.00 Chairman's Closing Remarks and Close of Day Two

[DOWNLOAD BROCHURE](#) for presentation details

www.therapeutics-rna.com

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>